
SPTX Stock Forecast & Price Target
SPTX Analyst Ratings
Bulls say
Seaport Therapeutics is poised for success as their GlyphAllo and GlyphAgo drugs have shown promise in Phase 1 trials and have the potential to serve a growing market in need of more effective and safer treatments for mental health disorders. With top-line data expected in 1H27 and 2028 respectively, investors can expect potential revenue growth from these drugs and their differentiated lymphatic-targeting prodrug technology. Additionally, Seaport's diversified pipeline and strong management team make them an attractive target for potential M&A interest, further adding to their growth potential.
Bears say
Seaport Therapeutics is a clinical-stage therapeutics company with a pipeline of neuropsychiatric drugs that utilize lymphatic-targeting technology. While the company's collaboration with PureTech Health and recent Series A financing may suggest promise, its competitors and uncertain market acceptance pose significant risks for future profitability. Additionally, the company's lack of current revenue and uncertain cash flow projections make it a risky investment in the near-term.
This aggregate rating is based on analysts' research of Seaport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
SPTX Analyst Forecast & Price Prediction
Start investing in SPTX
Order type
Buy in
Order amount
Est. shares
0 shares